Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% Following Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK)’s share price fell 14.1% during mid-day trading on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares changed hands during mid-day trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reduced their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft decreased their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a report on Tuesday, August 12th. Peel Hunt reaffirmed a “buy” rating and set a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a report on Friday. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of GBX 2,416.

Insider Buying and Selling

In related news, insider Laura Balan Balan bought 3,500 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was acquired at an average price of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah purchased 315,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was bought at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150. Insiders bought 332,500 shares of company stock valued at $533,130,500 over the last 90 days. Company insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The stock has a 50 day simple moving average of GBX 1,730.88 and a two-hundred day simple moving average of GBX 1,893.97. The company has a market cap of £3.50 billion, a price-to-earnings ratio of 9.47, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.